Aussie grey nomads, campers warned as deadly threat prompts new campaign
Peter's wife, Sonia, is now warning others not to take mosquito bites lightly. "Not enough people are aware of the severity of the viruses that mozzies carry," Sonia told Yahoo News. "Most people have never even heard of MVE. We hadn't. Awareness is the only way to start imprinting the message with people: Prevent bites. It's the only way to protect yourself."
The couple had made regular caravanning trips through the Kimberley, Pilbara, and Gascoyne areas, now included in the free repellent dispenser trial. "We had made many trips to Broome, the Dampier Peninsula, Kununurra and the Gibb River Road," Sonia said. "It was one of our favourite destinations."
During their final three-week trip together, there were no warning signs. "Pete never said mosquitoes really bothered him. There wasn't a particular bite on him that we were aware of," she said. "I always get smashed by mosquitoes, though."
Tragically, Peter contracted MVE — a rare but potentially fatal virus carried by mosquitoes — and lost his life not long after. Since 2023, there have been 12 recorded cases of MVE in WA, resulting in five deaths.
The new initiative will see free mosquito repellent dispensers made available to eligible community organisations in high-risk areas, such as caravan parks, sporting clubs, outdoor cinemas and alfresco venues. It is timed to coincide with the annual "grey nomad" season, when thousands of older travellers head north during the winter months — a group considered particularly vulnerable to mosquito-borne illness.
A State-wide rollout is planned for 2026, following the initial trial across the Kimberley, Pilbara and Gascoyne. WA Health continues to detect MVE activity through its mosquito and sentinel chicken surveillance programs. Although winter is usually a lower-risk period, 2025 has been an unusual year, prompting authorities to reinforce prevention messages.
A WA Health spokesperson told Yahoo that the northern dry season, which generally represents a lower risk period for mosquito-borne viruses, has been an unusual year in 2025.
"Whilst rare, infection can cause a very serious, potentially fatal, disease. Individuals who survive are often left with severe neurological deficits or disability," they said.
"Residents and travellers heading north need to take extra precautions to prevent mosquito bites by wearing long, loose-fitting, light-coloured clothing, avoid areas where mosquitoes are in high numbers and apply an effective insect repellent to all areas of exposed skin.
🦠 Family's Bali nightmare amid disease outbreak in tourist hotspots
‼️ Scientists use toxins to kill off world's most dangerous creature
🦟 Could this tiny gadget reduce itch caused by mosquito bites?
"WA Health is also encouraging local governments and larger businesses/corporate organisations to make insect repellent readily accessible to the public and employees in high-risk locations, to reduce the risk of mosquito-borne disease.
A limited number of repellent dispensers are available, free of charge, to eligible community groups/organisations in Kimberley, Pilbara, and Gascoyne to participate in this important Fight the Bite initiative.
Sonia, meanwhile, hopes sharing her family's story can help save others. "Prevent bites — it's the only way," she said.
Love Australia's weird and wonderful environment? 🐊🦘😳 Get our new newsletter showcasing the week's best stories.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Aethlon Medical Inc (AEMD) Q1 2026 Earnings Call Highlights: Strategic Focus on Australian ...
Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aethlon Medical Inc (NASDAQ:AEMD) has made significant progress in its Australian oncology trial, with the first cohort of patients completing treatment without any device deficiencies or serious adverse events. The company has received formal approval from India's CDSCO to initiate an oncology trial, although they have decided to focus resources on the Australian trial for strategic reasons. Aethlon Medical Inc (NASDAQ:AEMD) has significantly reduced operating expenses by approximately 32%, primarily through payroll savings and reduced legal and consulting fees. The company is actively exploring the use of its hemo purifier for broader applications, including long COVID, and has presented promising pre-clinical data at a symposium. Aethlon Medical Inc (NASDAQ:AEMD) benefits from a 43% cash tax rebate in Australia, which helps offset research costs and makes conducting trials there financially advantageous. Negative Points The decision to not proceed with the Indian trial may delay potential strategic partnerships or regulatory approvals, as the company focuses solely on the Australian trial. Despite cost reductions, Aethlon Medical Inc (NASDAQ:AEMD) will still need to raise additional funds to continue its clinical research, as it does not yet have approved products for sale. The company faces challenges in accelerating patient enrollment in its Australian trial, although efforts are being made to address this through additional sites and recruitment strategies. The efficacy of the hemo purifier in actual clinical settings remains to be proven, as pre-clinical results may not directly translate to patient outcomes. Aethlon Medical Inc (NASDAQ:AEMD) is still in the early stages of its clinical trials, and it may take time to gather sufficient data to inform dosing and treatment effects. Q & A Highlights Warning! GuruFocus has detected 2 Warning Sign with AEMD. Q: Can you confirm if the primary endpoint of the Australian study is safety, and if the first cohort has shown no adverse events related to the hemo purifier treatment? A: Yes, the primary endpoint is safety. We have successfully passed the first cohort with no adverse events, and an independent data safety monitoring board has recommended moving forward to the second cohort. (Dr. Steven La Rosa, Chief Medical Officer) Q: The pre-clinical data showed a 98.5% removal of extracellular vesicles in a simulated treatment. Should we expect similar results in the clinical study with actual patients? A: Laboratory results often differ from clinical outcomes. The true test will be the reduction observed in actual patients, and we hope to have data from the first cohort soon. (Dr. Steven La Rosa, Chief Medical Officer) Q: With the decision not to proceed with the Indian trial, what does this mean for your cash needs and strategic focus? A: We will need to continue raising funds, ideally with strategic partners. The decision to halt the Indian trial was more about avoiding delays in approval processes rather than cost savings. (Jim Frakes, CEO and CFO) Q: Are there any advantages to conducting clinical research in Australia compared to India, especially regarding costs and incentives? A: Australia offers a significant tax rebate of about 43%, which is not available in India. This rebate can make conducting research in Australia more cost-effective despite lower hospital costs in India. (Jim Frakes, CEO and CFO) Q: What efforts are being made to accelerate patient enrollment in the Australian trial? A: We are actively working on several initiatives, including pre-screening logs, recruiting additional sites, and using clinical trial liaisons and social media campaigns to speed up enrollment. (Dr. Steven La Rosa, Chief Medical Officer) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
4 minutes ago
- Yahoo
Legionnaires' disease cluster in New York City causes a 4th death, sickens over 100 people. What is it, and how do you get it?
NYC health officials identified the buildings connected to the outbreak, one being Harlem Hospital. A fourth person has died, and over 100 people have been sickened with Legionnaires' disease — 15 of them currently hospitalized — amid an outbreak in central Harlem in New York City, health officials said Thursday. The disease was initially detected on July 25. Since then, the New York City Department of Health has been investigating the cluster and linked it to 12 cooling towers in 10 Harlem buildings. Cooling towers are structures containing water and a fan that are used to regulate a building's temperature. Eleven of the 12 cooling towers that tested positive for the bacteria that cause Legionnaires' disease have been remediated, with the last one currently undergoing remediation, acting Health Commissioner Michelle Morse said during a Thursday news conference. Health officials released a list on Thursday that identifies the 10 buildings connected to the outbreak: BRP Companies, Lafayette Development LLC, 2239 Adam Clayton Powell Jr. Blvd. BVK, 215 W. 125th St. Commonwealth Local Development, 301 W. 124th St. CUNY — City College Marshak Science Building, 181 Convent Ave. Harlem Center Condo, 317 Lenox Ave. NYC Economic Development Corporation, 40 W. 137th St. NYC Health Department Central Harlem Sexual Health Clinic, 2238 Fifth Ave. NYC Health + Hospitals/Harlem, 506 Lenox Ave. The New York Hotel Trades Council Harlem Health Center, 133 Morningside Ave. Wharton Properties, 100 W. 125th St. (three of eight towers) Overall, the following ZIP codes have been affected in Harlem: 10027, 10030, 10035, 10037 and 10039. 'We are continuing to urge all New Yorkers who live or work in the identified ZIP codes in central Harlem who have flu-like symptoms to contact a health care provider immediately,' Morse said. 'New Yorkers should know the air is safe to breathe, and we are seeing declining numbers of new cases each day,' New York City Mayor Eric Adams told the media. 'I want to thank the health workers who worked tirelessly to treat this community and make sure its residents are healthy.' What is Legionnaires' disease? It's a serious type of pneumonia, a lung infection, that is caused by Legionella bacteria. People can become sick from inhaling water vapor that's contaminated with Legionella bacteria. Less commonly, a person can get sick when water contaminated with the bacteria accidentally enters the lungs by aspiration. How does it spread? In general, Legionnaires' is not transmitted from person to person. Legionella can grow and spread in human-made water systems like showerheads and sink faucets, hot tubs, decorative fountains, complex and large plumbing systems and cooling towers, according to the Centers for Disease Control and Prevention. There are also factors that make it easier for Legionella to grow and survive in water, including: Biofilm, which is slime that enables germs to grow Temperatures from 77 degrees to 113 degrees Fahrenheit Not having enough disinfectant Slow or no water movement (read more from the CDC about how to prevent waterborne germs while away from your home) What are the symptoms of Legionnaires' disease? Symptoms usually appear in a person within two to 14 days after they've been exposed to the bacteria, the CDC says. Symptoms can be similar to other types of pneumonia, such as: Headache Muscle aches Shortness of breath Cough Fever Other symptoms can include confusion, diarrhea or nausea. Who is at risk of getting sick? Most healthy people exposed to Legionella don't become ill, according to the CDC's website. However, the following people are at increased risk of getting sick from the bacteria: People 50 years and older Current or former smokers People with specific health issues or conditions, like cancer, chronic lung disease, diabetes, kidney failure, liver failure and a weak immune system Diagnosis and treatment A chest X-ray can confirm if a person has pneumonia. But additional tests are needed to confirm if Legionella bacteria is the cause behind it, such as a urine test, or a lab test involving a sample from phlegm (sputum) or lung lavage (lung washing), according to the CDC. The disease is treatable with antibiotics, but hospital care is often needed.
Yahoo
an hour ago
- Yahoo
Why Teladoc (TDOC) Stock Is Trading Up Today
What Happened? Shares of digital medical services platform Teladoc Health (NYSE:TDOC) jumped 3.7% in the afternoon session after the company announced its acquisition of Telecare, an Australian virtual care provider, to expand its international footprint. The strategic acquisition of Telecare, an Australian virtual care provider, bolsters Teladoc's international presence, adding over 300 specialists across 30 specialties to its network. While the company stated the deal, which closed on August 8, is not expected to significantly impact its 2025 financial results, it strengthens its foothold in the Australian market where it has operated for over a decade. After the initial pop the shares cooled down to $7.59, up 4% from previous close. Is now the time to buy Teladoc? Access our full analysis report here, it's free. What Is The Market Telling Us Teladoc's shares are extremely volatile and have had 42 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 2 days ago when the stock gained 8.8% on the news that markets continued to rally as the latest inflation data reinforced expectations for a Federal Reserve rate cut as soon as September. The latest Consumer Price Index (CPI) report for July showed inflation holding steady, reinforcing market expectations that the Federal Reserve could begin cutting interest rates as soon as September. Lower interest rates generally stimulate the economy by making borrowing cheaper for consumers and businesses. This can lead to increased consumer spending and e-commerce activity, which directly benefits online retail and marketplace companies. The positive economic outlook fueled a broad-based rally, pushing the S&P 500 and Nasdaq to new record highs and lifting most growth-oriented technology stocks. Teladoc is down 20.2% since the beginning of the year, and at $7.59 per share, it is trading 47% below its 52-week high of $14.33 from February 2025. Investors who bought $1,000 worth of Teladoc's shares 5 years ago would now be looking at an investment worth $37.04. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.